What FSH Level Indicates Menopause vs. Perimenopause?

FSH levels must be interpreted in context, but as a general framework: during the reproductive years, FSH typically runs 3–10 IU/L in the early follicular phase. In perimenopause, FSH begins rising erratically—values may swing between 10 and 30+ IU/L from one cycle to the next. Confirmed menopause is typically associated with FSH consistently above 25–30 IU/L, often combined with cessation of periods for 12 consecutive months. Post-menopausal FSH commonly exceeds 40 IU/L and can reach 100–150 IU/L over time. Critically, a single elevated FSH reading does not confirm menopause, especially in women still having irregular periods. The Endocrine Society and NAMS both recommend repeat testing over time before drawing firm conclusions from FSH alone.

LH (luteinizing hormone) is produced by the same pituitary cells as FSH and follows a broadly similar trajectory during the menopausal transition—rising as ovarian estrogen output declines. However, LH typically rises less steeply than FSH in the perimenopause-to-menopause shift, and its ratio to FSH can itself be informative. In post-menopause, LH commonly stabilizes in the range of 15–60 IU/L. LH becomes particularly important when evaluating conditions that can mimic menopause: in polycystic ovary syndrome (PCOS), for example, LH is elevated relative to FSH (LH:FSH ratio >2:1) during the reproductive years, which is a distinct pattern from menopausal hormonal shifts. Tracking both hormones together provides a more complete picture than FSH alone.

Yes—this is one of the most clinically important points about perimenopausal hormone testing. During the menopausal transition, FSH levels are highly variable. A woman in early perimenopause might have an FSH of 35 IU/L in one cycle and 8 IU/L the next if her ovaries temporarily produce a surge of estradiol. This is why a single 'normal' FSH result does not rule out perimenopause, and a single 'high' FSH result does not confirm menopause. The SWAN study documented this variability extensively. Clinicians typically order repeat testing over several months, and often measure estradiol simultaneously, to build a reliable picture of hormonal status. If your FSH comes back 'normal' but you're experiencing classic perimenopausal symptoms, ask your provider about repeat testing.

These are three distinct stages. Perimenopause is the transitional period leading up to menopause, characterized by hormonal fluctuations, irregular menstrual cycles, and emerging symptoms like hot flashes and sleep disruption. It can begin in a woman's early-to-mid 40s (occasionally earlier) and last 2–10 years. Menopause is technically a single point in time: the moment when 12 consecutive months have passed without a menstrual period, caused by permanent cessation of ovarian follicular activity. It is diagnosed retrospectively. Post-menopause refers to all the years after that 12-month threshold. FSH and LH are most useful for confirming menopausal status in ambiguous cases (e.g., after hysterectomy without oophorectomy, or in women using hormonal contraception that masks cycle changes).

Premature ovarian insufficiency (POI), formerly called premature ovarian failure, occurs when the ovaries stop functioning normally before age 40. It affects approximately 1% of women. Unlike natural menopause, POI is not always permanent—ovarian function can fluctuate, and spontaneous pregnancy can still occur in some cases. POI is defined by FSH above 25 IU/L on two separate occasions at least 4 weeks apart, combined with amenorrhea or oligomenorrhea for at least 4 months, in a woman under 40. Causes include autoimmune conditions, genetic factors (e.g., Turner syndrome, fragile X premutation), and prior chemotherapy or radiation. Early menopause (ages 40–45) is distinct—it is permanent and does not share POI's variable course. Both conditions warrant urgent evaluation and typically require hormone therapy to protect bone and cardiovascular health.

Yes, significantly. Combined oral contraceptives (containing both estrogen and progestin), hormonal patches, rings, and hormonal IUDs all suppress FSH and LH through negative feedback on the hypothalamic-pituitary axis. If you are currently using hormonal contraception, FSH and LH results will appear artificially low and cannot reliably be used to assess menopausal status or ovarian reserve. The standard recommendation is to stop hormonal contraception for at least 4–6 weeks (some clinicians recommend longer) before testing FSH/LH for menopausal evaluation. This creates a practical dilemma for women in their late 40s using contraception for symptom management—discuss the testing strategy and timing with your provider.

FSH and LH are typically just two pieces of a broader hormonal picture. A comprehensive menopausal workup often includes: Estradiol (E2)—the primary ovarian estrogen; levels below 30 pg/mL alongside elevated FSH are consistent with menopause. AMH (anti-Müllerian hormone)—a more stable marker of ovarian reserve that doesn't fluctuate with the menstrual cycle; particularly useful in younger women evaluating fertility potential. TSH (thyroid-stimulating hormone)—thyroid dysfunction (both hypothyroidism and hyperthyroidism) can cause menstrual irregularities and symptoms that closely mimic perimenopause, making it essential to rule out. Prolactin—elevated prolactin can suppress FSH/LH and cause amenorrhea. Complete metabolic panel and lipid panel—because estrogen decline increases cardiovascular risk. Your provider will determine which combination is appropriate based on your symptoms and age.

When the uterus has been surgically removed (hysterectomy), the traditional clinical marker—12 consecutive months without a period—is no longer available. In this case, FSH and LH testing becomes the primary diagnostic tool for menopausal status. If the ovaries were also removed (bilateral oophorectomy), surgical menopause occurs immediately regardless of age, and FSH/LH will rapidly rise into the post-menopausal range within days to weeks. If the ovaries were conserved (hysterectomy without oophorectomy), the ovaries continue to function and decline naturally, but menstrual period-based dating is impossible. Serial FSH testing—ideally measured 4–6 weeks apart—is used to track the hormonal transition. Some clinicians also measure estradiol and track symptoms to supplement FSH data in this population.

Yes, and this is an area of active research. The SWAN study—which followed a diverse cohort of over 3,000 women across multiple ethnic groups—found meaningful differences in the timing and hormonal characteristics of the menopausal transition. African American women, on average, entered perimenopause earlier and experienced more vasomotor symptoms. Japanese and Chinese American women reported fewer hot flashes. There is also emerging evidence of differences in FSH trajectory between groups, though reference ranges used in most clinical assays have historically been developed from predominantly White populations. The NAMS acknowledges these differences and encourages clinicians to interpret hormonal results in the context of individual patient backgrounds rather than applying universal thresholds rigidly.

For a woman in her reproductive years who is menstruating regularly, FSH is typically measured on day 2 or 3 of the menstrual cycle (day 1 = first day of period). At that point, a normal FSH is generally considered to be below 10 IU/L for most assays, though ranges vary slightly by laboratory. Values between 10–15 IU/L may suggest diminished ovarian reserve, particularly in the context of fertility evaluation. Values above 15–20 IU/L on day 3 are associated with significantly reduced ovarian reserve and may affect IVF candidacy. However, FSH should always be interpreted alongside estradiol—a high day-3 estradiol can suppress FSH to a falsely reassuring low value through negative feedback. This nuance is why FSH alone is not considered the gold standard for ovarian reserve assessment; AMH and antral follicle count on ultrasound provide additional information.

Yes. FSH and LH are not exclusively female hormones—they play essential roles in male reproductive physiology as well. In men, LH stimulates Leydig cells in the testes to produce testosterone, while FSH stimulates Sertoli cells and supports spermatogenesis. Normal male FSH ranges are typically 1.5–12.4 IU/L and LH 1.7–8.6 IU/L (lab-specific ranges apply). Elevated FSH in men often signals primary testicular failure—the testes are not responding to FSH stimulation, prompting the pituitary to produce more. Low FSH and LH in men (hypogonadotropic hypogonadism) suggests the problem originates in the pituitary or hypothalamus rather than the testes. Male FSH/LH evaluation is relevant in infertility workups and testosterone deficiency diagnosis. This calculator focuses on the female menopausal context, but the underlying hormonal logic is shared.

You should seek medical evaluation if: your FSH is elevated and you are under 40 (possible POI, which requires prompt investigation); you have stopped having periods for more than 3 months at any reproductive age without a clear cause; you are experiencing severe vasomotor symptoms, significant mood changes, or sleep disruption that affects daily functioning; your test results are outside the reference range and you don't understand the interpretation; or you're planning a pregnancy and concerned about ovarian reserve. For menopausal health, a gynecologist or reproductive endocrinologist is the appropriate specialist. For younger women with suspected POI, a reproductive endocrinologist is strongly recommended. A general practitioner or internist can order and initially interpret FSH/LH tests, but specialist input is valuable for management decisions including hormone therapy, bone health, and cardiovascular risk.